153 related articles for article (PubMed ID: 29180185)
21. Elevated O-GlcNAcylation stabilizes FOXM1 by its reduced degradation through GSK-3β inactivation in a human gastric carcinoma cell line, MKN45 cells.
Inoue Y; Moriwaki K; Ueda Y; Takeuchi T; Higuchi K; Asahi M
Biochem Biophys Res Commun; 2018 Jan; 495(2):1681-1687. PubMed ID: 29196265
[TBL] [Abstract][Full Text] [Related]
22. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.
Pan H; Zhu Y; Wei W; Shao S; Rui X
World J Surg Oncol; 2018 Mar; 16(1):59. PubMed ID: 29554906
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.
Aydin D; Bilici A; Yavuzer D; Kefeli U; Tan A; Ercelep O; Mert A; Yuksel S; Ozcelik M; Isik D; Surmeli H; Odabasi H; Aliustaoglu M
Clin Transl Oncol; 2015 Aug; 17(8):604-11. PubMed ID: 25786367
[TBL] [Abstract][Full Text] [Related]
24. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.
Karan D; Lin FC; Bryan M; Ringel J; Moniaux N; Lin MF; Batra SK
Int J Oncol; 2003 Nov; 23(5):1365-71. PubMed ID: 14532978
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma.
Sun HC; Li M; Lu JL; Yan DW; Zhou CZ; Fan JW; Qin XB; Tang HM; Peng ZH
Oncol Rep; 2011 Jun; 25(6):1533-9. PubMed ID: 21431285
[TBL] [Abstract][Full Text] [Related]
26. MiR-320a inhibits gastric carcinoma by targeting activity in the FoxM1-P27KIP1 axis.
Wang Y; Zeng J; Pan J; Geng X; Li L; Wu J; Song P; Wang Y; Liu J; Wang L
Oncotarget; 2016 May; 7(20):29275-86. PubMed ID: 27086911
[TBL] [Abstract][Full Text] [Related]
27. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
[TBL] [Abstract][Full Text] [Related]
28. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
[TBL] [Abstract][Full Text] [Related]
29. FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1.
Zeng J; Wang L; Li Q; Li W; Björkholm M; Jia J; Xu D
J Pathol; 2009 Aug; 218(4):419-27. PubMed ID: 19235838
[TBL] [Abstract][Full Text] [Related]
30. ADAM 10 is associated with gastric cancer progression and prognosis of patients.
Wang YY; Ye ZY; Li L; Zhao ZS; Shao QS; Tao HQ
J Surg Oncol; 2011 Feb; 103(2):116-23. PubMed ID: 21259244
[TBL] [Abstract][Full Text] [Related]
31. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer.
Chu XY; Zhu ZM; Chen LB; Wang JH; Su QS; Yang JR; Lin Y; Xue LJ; Liu XB; Mo XB
Acta Histochem; 2012 Dec; 114(8):755-62. PubMed ID: 22326401
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-630 Suppresses Epithelial-to-Mesenchymal Transition by Regulating FoxM1 in Gastric Cancer Cells.
Feng J; Wang X; Zhu W; Chen S; Feng C
Biochemistry (Mosc); 2017 Jun; 82(6):707-714. PubMed ID: 28601080
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of FOXM1 Is a Potential Prognostic Marker in Male Breast Cancer.
Abdeljaoued S; Bettaieb I; Nasri M; Adouni O; Goucha A; El Amine O; Boussen H; Rahal K; Gamoudi A
Oncol Res Treat; 2017; 40(4):167-172. PubMed ID: 28376490
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer.
Kong FF; Qu ZQ; Yuan HH; Wang JY; Zhao M; Guo YH; Shi J; Gong XD; Zhu YL; Liu F; Zhang WY; Jiang B
Oncol Rep; 2014 Jun; 31(6):2660-8. PubMed ID: 24715097
[TBL] [Abstract][Full Text] [Related]
35. FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1.
Chai N; Xie HH; Yin JP; Sa KD; Guo Y; Wang M; Liu J; Zhang XF; Zhang X; Yin H; Nie YZ; Wu KC; Yang AG; Zhang R
Biochem Biophys Res Commun; 2018 Jun; 500(4):924-929. PubMed ID: 29705704
[TBL] [Abstract][Full Text] [Related]
36. Correlated low IGF2BP1 and FOXM1 expression predicts a good prognosis in lung adenocarcinoma.
Huang H; Wang D; Guo W; Zhuang X; He Y
Pathol Res Pract; 2019 Jul; 215(7):152433. PubMed ID: 31085008
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance and positive correlation of FoxM1 and Her-2 expression in gastric cancer.
Li X; Tang D; Yao Y; Qi W; Liang J
Clin Exp Med; 2014 Nov; 14(4):447-55. PubMed ID: 24101296
[TBL] [Abstract][Full Text] [Related]
38. SUMO-specific protease 6 promotes gastric cancer cell growth via deSUMOylation of FoxM1.
Song JG; Xie HH; Li N; Wu K; Qiu JG; Shen DM; Huang CJ
Tumour Biol; 2015 Dec; 36(12):9865-71. PubMed ID: 26164001
[TBL] [Abstract][Full Text] [Related]
39. The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells.
Hu CJ; Wang B; Tang B; Chen BJ; Xiao YF; Qin Y; Yong X; Luo G; Zhang JW; Zhang D; Li S; He F; Yang SM
Biochim Biophys Acta; 2015 Mar; 1849(3):290-9. PubMed ID: 25482013
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-216b is downregulated in hepatocellular carcinoma and inhibits HepG2 cell growth by targeting Forkhead box protein M1.
Zheng WW; Zhou J; Zhang CH; Liu XS
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2541-50. PubMed ID: 27383303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
